Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
8.31
-0.09 (-1.07%)
At close: Oct 23, 2026, 4:00 PM EDT
8.24
-0.07 (-0.82%)
After-hours: Oct 23, 2026, 5:31 PM EDT
Contineum Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
51
Market Cap
312.63M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Orchestra BioMed Holdings | 31.98M |
| Arcturus Therapeutics Holdings | 29.37M |
| X4 Pharmaceuticals | 15.85M |
| Surrozen | 11.51M |
| Opus Genetics | 9.86M |
| YD Bio | 1.24M |
| Artiva Biotherapeutics | 251.00K |
CTNM News
- 8 days ago - Contineum price target raised to $30 from $24 at Jones - TheFly
- 9 days ago - Contineum downgraded to Neutral from Outperform at Baird - TheFly
- 10 days ago - Contineum downgraded to Neutral from Outperform at Baird - TheFly
- 23 days ago - Jones sees greater room for Contineum’s PIPE-791 to differentiate - TheFly
- 24 days ago - Contineum Therapeutics Inc trading resumes - TheFly
- 24 days ago - Contineum Therapeutics Inc trading halted, volatility trading pause - TheFly
- 26 days ago - Contineum price target lowered to $17 from $18 at Morgan Stanley - TheFly
- 4 weeks ago - Contineum resumed at Early-Stage Biotech at Goldman Sachs - TheFly